Innovating. Developing. Delivering.
At MediWound, we’re redefining wound care with next-generation enzymatic treatments that selectively remove escar tissue while preserving healthy tissue. Our patient-centered solutions for burns and chronic wounds are designed to accelerate healing, improve outcomes, and lower healthcare costs.
As a fully integrated biotechnology company — we’re uniquely equipped to deliver transformative therapies at scale and broaden access to advanced wound care around the world.
With a commercial product and strong pipeline, we are expanding our platform into new indications, addressing significant unmet medical needs, and improving patients’ lives worldwide.
Recent Updates
Our Products
Redefining the
Standard of Care
Standard of Care

NexoBrid®
A New Paradigm in Treatment of Severe Burns
Indication: Eschar removal in deep partial-thickness and full-thickness thermal burns
Classification: Orphan biological drug
Target Audience: Hospitalized patients
Status: U.S./EU/Japan approved
EMAFDA

EscharEx®
Next-Generation Enzymatic Therapy Candidate for Wound Care
Indication: Debridement of chronic/hard-to-heal wounds
Classification: Biological drug
Target Audience: Patients in all wound care settings
Status: Phase 3 in VLU ongoing; planned DFU trial
Phase IIPhase III
Research & Development
• In Vitro / In Vivo Models: Advanced efficacy and safety testing
• Analytical Methods: Precise characterization and quality control
• Product Formulation: Optimized for stability, ease of use, and therapeutic performance
Manufacturing
• cGMP Certified: Compliant with global standards
• Aseptic Processing: Sterile, high-integrity production
• Development Suites: Advanced formulation and scale-up
Commercialization
• U.S.: Strategic partnership with Vericel Corp
• Europe: Direct sales; PMI promotion in DACH region
• Global: Collaborations in Japan, India, Australia, and additional markets
Summing Up Success
MediWound Facts and Figures
Publications
0
Products
0
Countries
0
Strategic Partnerships
0
Revenue in 2024
$
0
M